Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of DA-1229_01 (Evogliptin/Metformin) in Healthy Subjects
NCT05739903Phase 1Unknown
- Sponsor
- Dong-A ST
- Start
- Mar 2023
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DA5221-B2 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Dong-A ST. Primary endpoints: Area Under the Concentration-time Curve from time zero to last quantifiable concentration and Maximum Plasma Concentration. Status: unknown.
02
Drugs
DA5221-B2
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05739903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05739903.